The U.S. Treasury Department announces new regulations to curb tax-avoiding corporate inversions, i.e., where U.S. companies slash their tax bills by claiming a new tax home overseas, though their core operations and management remain in the United States. The pending $160 billion merger of Pfizer Inc. and Allergan, Plc could be cancelled because of these new rules.